You are here

Small Molecule Antiviral Agents Against Flaviviruses

Award Information
Agency: Department of Defense
Branch: Army
Contract: W81XWH-12-C-0006
Agency Tracking Number: A112-106-0271
Amount: $100,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: A11-106
Solicitation Number: 2011.2
Timeline
Solicitation Year: 2011
Award Year: 2012
Award Start Date (Proposal Award Date): 2011-11-14
Award End Date (Contract End Date): N/A
Small Business Information
3913 Todd Lane Suite 312
Austin, TX -
United States
DUNS: 611930244
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 Joseph Krebs
 Director
 (512) 707-8993
 jkrebs@biooscientific.com
Business Contact
 Lance Ford
Title: Manager
Phone: (512) 707-8993
Email: lford@biooscientific.com
Research Institution
 Stub
Abstract

Flaviviruses are a major health threat worldwide. This family of RNA viruses causes a variety of deadly diseases such as Dengue Fever, Yellow Fever, West Nile virus, and Tick-borne Encephalitis. There are currently no effective means to control these viruses. New drugs to counteract these viruses are desperately needed. Flaviviruses block the body's immune response by inhibiting nuclease enzymes which degrade viral RNA. Our goal is to identify small molecules to disrupt these flavivirus nuclease inhibitors to increase the cell's antiviral response. We will develop a high-throughput fluorescence polarization assay to identify novel small molecule disruptors of the viral inhibitor from compound libraries. We will also identify novel RNA-disrupting compounds using computer modeling techniques. The novel drugs identified will be synthesized and tested using flavivirus-infected cells in tissue culture to confirm biological activity.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government